Claude Wischik
Vorstandsvorsitzender bei TauRx Pharmaceuticals Ltd.
Aktive Positionen von Claude Wischik
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TauRx Pharmaceuticals Ltd.
TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Vorstandsvorsitzender | 01.01.2002 | - |
Vorsitzender | 01.01.2002 | - | |
Gründer | 01.01.2002 | - | |
TauRx Therapeutics Ltd.
TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Vorsitzender | 01.01.2002 | - |
Gründer | 01.01.2002 | - |
Karriereverlauf von Claude Wischik
Statistik
International
Singapur | 3 |
Operativ
Founder | 2 |
Chairman | 2 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
TauRx Pharmaceuticals Ltd.
TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Health Technology |
TauRx Therapeutics Ltd.
TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Health Technology |
- Börse
- Insiders
- Claude Wischik
- Erfahrung